Login to Your Account



Pharma: Clinic roundup


Tuesday, May 6, 2014
UCB SA, of Brussels, Belgium, reported results from the PRECiSE 3 seven-year open-label extension trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription